Back to Trades
Total Value
$4.3M
Net $2.4M sold
Filing Date
Jul 17, 2026
1 transaction
Sales
$2.4M
1 transaction
Trade Summary
On Jul 15, 2026, LO FRANCIS, Chief People Officer, sold $4.3M of Adaptive Biotechnologies Corp (ADPT) across 1 transaction. The filing covers Common Stock and reflects net selling of $2.4M. Reported prices ranged from $7.80 to $22.59. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Adaptive Biotechnologies Corp
- Ticker Symbol
- ADPT
- CIK
- 0001478320
Insider Information
- Name
- LO FRANCIS
- Role
- Chief People Officer
- Location
- SEATTLE, WA
Filing Details
- Filing Date
- Jul 17, 2026
- Transaction Date
- Jul 15, 2026
- Accession Number
- 0001780660-26-000019
- Form Type
- 4
- Net Trading Amount
- -$2.4M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock | 59,374 | $7.80 | Exercise | $463.1K |
| Jul 15, 2026 | Common Stock | 23,677 | $12.14 | Exercise | $287.4K |
| Jul 15, 2026 | Common Stock | 22,711 | $8.46 | Exercise | $192.1K |
| Jul 15, 2026 | Common Stock | 105,762 | $22.59 | Sale | $2.4M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | ADPT derivative | 59,374 | $7.80 | Exercise | $463.1K |
| Jul 15, 2026 | ADPT derivative | 23,677 | $12.14 | Exercise | $287.4K |
| Jul 15, 2026 | ADPT derivative | 22,711 | $8.46 | Exercise | $192.1K |
Want live alerts when LO FRANCIS trades again?
Download Insider Trades to track ADPT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- (F2)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- (F3)The option is fully vested and exercisable.
- (F4)The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.